Q-omics provides the consensus-scored CACNA1C-IT3 profile across patient tissues and cancer cell-line models. CACNA1C-IT3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CACNA1C-IT3 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, CACNA1C-IT3 RNA expression shows 15,903 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where CACNA1C-IT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA1C-IT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA1C-IT3 survival associations across molecular data types. CACNA1C-IT3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA1C-IT3 RNA expression–survival associations across cancer types. High CACNA1C-IT3 expression shows unfavorable associations in LIHC, SKCM, BLCA, THCA and ACC, but favorable associations in LAML. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CACNA1C-IT3 RNA expression.
This table summarizes CACNA1C-IT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA1C-IT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA1C-IT3 shows higher tumor expression in HNSC. The HNSC box plot shows higher CACNA1C-IT3 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .035).
This table shows molecular features associated with CACNA1C-IT3 in patient tissues and cancer cell lines. In patient samples, CACNA1C-IT3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
